947.5000 -4.45 (-0.47%)
NSE Sep 11, 2025 15:06 PM
Volume: 98,440
 

HDFC Securities
Incremental revenues from the front-end in the US, and a sequential uptick in gAbilify sales led to 25% YoY revenue growth in 1QFY17. EBITDA at Rs 1.5bn was up 55% YoY and margins improved to 21.3% ( 423bps). Driven by strong operating performance, PAT grew 48% YoY to Rs 1bn.
Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.
More from Alembic Pharmaceuticals Ltd.
Recommended